Third Death in Sarepta Gene Therapy Trial for Limb-Girdle Muscular Dystrophy
By
randycupertino
Toasted just enough. A reliable bake, gently seasoned.
Summary
A 51-year-old patient in a Phase I study of Sarepta's gene therapy for Limb-Girdle muscular dystrophy Type 2E has died from acute liver toxicity, marking the third death associated with the company's gene therapies.
Key quotes
· 2 pulledA third patient, a 51 year-old in a Phase I study of SRP-9004 for Limb-Girdle muscular dystrophy Type 2E, has died from a Sarepta gene therapy.
the most recent death was caused by acute liver toxicity, Sarepta Therapeutics Inc. spokesperson Tracy Sorrentino told BioCentury.
You might also wanna read
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
bit.ly·1h ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·1h ago
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
bbc.co.uk·4h ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·6h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h ago